ReviewCancer metastasis reviews2019
Immunotherapy in pediatric acute lymphoblastic leukemia.
Review in Cancer metastasis reviews, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 119 citations in OpenAlex.
- T cell-engaging bispecific antibodies for myeloid malignancies: Targets, formats, and clinical challenges.Cell reports. Medicine · 2026Review
- Redefining pediatric leukemia care - innovations in risk assessment and targeted treatment: a narrative review.Annals of medicine and surgery (2012) · 2026Review
- Nomogram-based prediction of asparaginase-associated pancreatitis in children with acute lymphoblastic leukemia: a retrospective study.Frontiers in pharmacology · 2026Article
- Regeneration of Peripheral Blood T-Cell Subpopulations in Children After Completion of Acute Lymphoblastic Leukemia Treatment.International journal of molecular sciences · 2025Article
- Outcomes of hematopoietic stem cell transplantation in pediatric acute lymphoblastic leukemia: a multicenter Brazilian cohort study.Bone marrow transplantation · 2025Article
- Treatment-related mutagenic processes in acute lymphoblastic leukemia.Haematologica · 2025Review
- Expression and treatment of ROR1+ cells with bispecific T-cell engagers in pediatric acute lymphoblastic leukemia.Blood advances · 2025Article
- Down-regulation of circMUC16 inhibited the progression of ALL via interaction with miR-1182 and TPPP3.Annals of hematology · 2025Article
- Article
- Fertility assessment in long-term young female survivors with hematological disease after allogeneic hematopoietic cell transplantation: a single-center real-life cross-sectional study.Annals of hematology · 2025Article
- The effects of bone marrow humoral components of B-cell acute lymphoblastic leukemia patients on natural killer cell suppression.Immunologic research · 2025Article
- Transcriptome-based immune subtypes reveal the heterogeneity of tumor microenvironment in pediatric B-cell acute lymphocytic leukemia.Frontiers in oncology · 2025Article
- Prognostic value, biological role, and mechanisms of LCN2 in childhood acute lymphoblastic leukemia.American journal of cancer research · 2025Article
- Therapeutic Significance of NLRP3 Inflammasome in Cancer: Friend or Foe?International journal of molecular sciences · 2024Review
- Perspectives of pediatric oncologists on referral for CAR-T therapy: a mixed methods pilot study.JNCI cancer spectrum · 2024Article
- Article
- The Role of the JAK-STAT Pathway in Childhood B-Cell Acute Lymphoblastic Leukemia.International journal of molecular sciences · 2024Review
- Unraveling resistance mechanisms in anti-CD19 chimeric antigen receptor-T therapy for B-ALL: a novel in vitro model and insights into target antigen dynamics.Journal of translational medicine · 2024Article
- Advancements in the impact of human microbiota and probiotics on leukemia.Frontiers in microbiology · 2024Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The 5-year survival rate for children and adolescents with acute lymphoblastic leukemia (ALL) has improved to more than 90% in high-income countries. However, further increases in the intensity of conventional chemotherapy would be associated with significant adverse effects; therefore, novel approaches are necessary. The last decade has seen significant advances in targeted therapy with immunotherapy and molecular therapeutics, as well as advances in risk stratification for therapy based on somatic and germline genetic analysis and monitoring of minimal residual disease. For immunotherapy, the approval of antibody-based therapy (with blinatumomab in 2014 and inotuzumab ozogamicin in 2017) and T cell-based therapy (with tisagenlecleucel in 2017) by the US Food and Drug Administration has significantly improved the response rate and outcomes in patients with relapsed/refractory B-ALL. These strategies have also been tested in the frontline setting, and immunotherapy against a new ALL-associated antigen has been developed. Incorporating effective immunotherapy into ALL therapy would enable the intensity of conventional chemotherapy to be decreased and thereby reduce associated toxicity, leading to further improvement in survival and quality of life for patients with ALL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.